Ulrich Rodeck

10.9k total citations · 1 hit paper
166 papers, 8.9k citations indexed

About

Ulrich Rodeck is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Ulrich Rodeck has authored 166 papers receiving a total of 8.9k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Molecular Biology, 61 papers in Oncology and 29 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Ulrich Rodeck's work include HER2/EGFR in Cancer Research (20 papers), Cell Adhesion Molecules Research (20 papers) and Monoclonal and Polyclonal Antibodies Research (17 papers). Ulrich Rodeck is often cited by papers focused on HER2/EGFR in Cancer Research (20 papers), Cell Adhesion Molecules Research (20 papers) and Monoclonal and Polyclonal Antibodies Research (17 papers). Ulrich Rodeck collaborates with scholars based in United States, Germany and Italy. Ulrich Rodeck's co-authors include Meenhard Herlyn, Csaba Kari, Hilary Koprowski, Adam P. Dicker, Gabor Kari, Monika Jost, Graziella Bellone, Pamela J. Jensen, Marlene R.D. Quadros and Tung O. Chan and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Ulrich Rodeck

163 papers receiving 8.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis

2019 341 citations Dan A. Erkes, Weijia Cai et al. Cancer Discovery profile →

Peers

Countries citing papers authored by Ulrich Rodeck

Since Specialization

Citations

This map shows the geographic impact of Ulrich Rodeck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ulrich Rodeck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ulrich Rodeck more than expected).

Fields of papers citing papers by Ulrich Rodeck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ulrich Rodeck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ulrich Rodeck. The network helps show where Ulrich Rodeck may publish in the future.

Co-authorship network of co-authors of Ulrich Rodeck

This figure shows the co-authorship network connecting the top 25 collaborators of Ulrich Rodeck. A scholar is included among the top collaborators of Ulrich Rodeck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ulrich Rodeck. Ulrich Rodeck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer 2023 ·Journal for ImmunoTherapy of Cancer ·(unknown), Miso Park, Magali Pederzoli-Ribeil, Uğur Eskiocak, (unknown), (unknown), M. A. McLaughlin, (unknown), (unknown), Zhen Liu, Benjamin Nicholson, (unknown), Huawei Qiu, Tim Clackson, Rónán C. O’Hagan, Ulrich Rodeck, Margaret Karow, Jennifer O’Neil, John C. Williams	8
2	Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis breakdown → 2019 ·Cancer Discovery ·Dan A. Erkes, Weijia Cai, Ileine M. Sanchez, Timothy J. Purwin, Corey Rogers, Conroy O. Field, Adam C. Berger, Edward J. Hartsough, Ulrich Rodeck, Emad S. Alnemri, Andrew E. Aplin	341
3	Tumor-Derived Extracellular Vesicles Require β1 Integrins to Promote Anchorage-Independent Growth 2019 ·iScience ·(unknown), Aejaz Sayeed, (unknown), Shiv Ram Krishn, (unknown), (unknown), (unknown), Peter A. McCue, Sudheer K. Molugu, Ulrich Rodeck, Adam P. Dicker, Lucia R. Languino	31
4	STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair 2018 ·Clinical Cancer Research ·(unknown), (unknown), David T. Hoang, Lei Gu, Vitali Alexeev, (unknown), (unknown), Jonathan R. Brody, Ulrich Rodeck, Carmen Bergom, (unknown), (unknown), William A. See, Sara M. Schmitt, Marja T. Nevalainen	46
5	The Triterpenoid RTA 408 is a Robust Mitigator of Hematopoietic Acute Radiation Syndrome in Mice 2015 ·Radiation Research ·Devorah C. Goldman, Vitali Alexeev, Lawrence H. Lash, Chandan Guha, Ulrich Rodeck, William H. Fleming	12
6	Radiation Protection of the Gastrointestinal Tract and Growth Inhibition of Prostate Cancer Xenografts by a Single Compound 2014 ·Molecular Cancer Therapeutics ·Vitali Alexeev, Lawrence H. Lash, (unknown), (unknown), (unknown), Keith W. Ward, Adam P. Dicker, Alban J. Linnenbach, Ulrich Rodeck	11
7	Differential regulation of p53 function by the N-terminal ΔNp53 and Δ113p53 isoforms in zebrafish embryos 2010 ·BMC Developmental Biology ·William R. Davidson, Csaba Kari, Qing Ren, (unknown), Adam P. Dicker, Ulrich Rodeck	20
8	Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice 2009 ·Cancer Research ·David Surguladze, Dhanvanthri S. Deevi, (unknown), Erik Corcoran, Su Wang, Mary Jane Plym, Yan Wu, Jacqueline Doody, David J. Mauro, Larry Witte, Klaus J. Busam, (unknown), Ulrich Rodeck, James R. Tonra	40
9	Nuclear factor κB inhibitors alleviate and the proteasome inhibitor PS-341 exacerbates radiation toxicity in zebrafish embryos 2009 ·Molecular Cancer Therapeutics ·(unknown), Gabor Kari, Qing Ren, Adam P. Dicker, Ulrich Rodeck	30
10	Malignant Transformation of Immortalized HaCaT Keratinocytes through Deregulated Nuclear Factor κB Signaling 2006 ·Cancer Research ·Qing Ren, Csaba Kari, Marlene R.D. Quadros, Randy Burd, Peter A. McCue, Adam P. Dicker, Ulrich Rodeck	45
11	2643 2006 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), Gabor Kari, (unknown), (unknown), Ulrich Rodeck, Adam P. Dicker	3
12	Cooperative Induction of a Tolerogenic Dendritic Cell Phenotype by Cytokines Secreted by Pancreatic Carcinoma Cells 2006 ·The Journal of Immunology ·Graziella Bellone, Anna Carbone, Carlo Smirne, (unknown), (unknown), Anna Novarino, Alessandra Stacchini, Oscar Bertetto, Giorgio Palestro, Claudio Sorio, Aldo Scarpa, G Emanuelli, Ulrich Rodeck	105
13	EGFR-dependent downregulation of bim in epithelial cells requires MAPK and PKC-δ activities 2006 ·Cancer Biology & Therapy ·Marlene R.D. Quadros, Sharon Connelly, Csaba Kari, Marc Abrams, Eric Wickstrom, Ulrich Rodeck	23
14	Epidermal Growth Factor Receptor-dependent Control of Keratinocyte Survival and Bcl-xL Expression through a MEK-dependent Pathway 2001 ·Journal of Biological Chemistry ·Monika Jost, (unknown), Csaba Kari, Lawrence Boise, Ulrich Rodeck	123
15	Transforming Growth Factor β Enhances Epithelial Cell Survival via Akt-dependent Regulation of FKHRL1 2001 ·Molecular Biology of the Cell ·Incheol Shin, Andrei V. Bakin, Ulrich Rodeck, Anne Brunet, Carlos L. Arteaga	153
16	A Central Role of Bcl-XL in the Regulation of Keratinocyte Survival by Autocrine EGFR Ligands 1999 ·Journal of Investigative Dermatology ·Monika Jost, Csaba Kari, Ulrich Rodeck, Reiner Class, Pamela J. Jensen	36
17	Enhancement of epidermal growth factor receptor expression on glioma cells by recombinant tumor necrosis factor α 1992 ·Cancer Immunology Immunotherapy ·Mitsuru Adachi, (unknown), Hans Bender, Derui Li, Ulrich Rodeck, Etty Benveniste, David Woo, Wolff Schmiegel, Dorothee Herlyn	23
18	A Mucin Containing the X, Y, and H Type 2 Carbohydrate Determinants Is Shed by Carcinoma Cells 1987 ·Hybridoma ·Ulrich Rodeck, Meenhard Herlyn, Karen Leander, (unknown), Hilary Koprowski	14
19	Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: immunologically mediated and effector cell-independent effects. 1987 ·PubMed ·Ulrich Rodeck, Meenhard Herlyn, Dorothee Herlyn, Carla F.M. Molthoff, Barbara Atkinson, Michael Varello, Zenon Steplewski, Hilary Koprowski	136
20	Metastatic but not primary melanoma cell lines grow in vitro independently of exogenous growth factors 1987 ·International Journal of Cancer ·Ulrich Rodeck, Meenhard Herlyn, Hans D. Menssen, Richard W. Furlanetto, Hilary Koprowski	122

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact